He was labelled as an undifferentiated autoimmune disorder by the medical team and given a trial of prednisolone 30mg to which his CRP fell from 265 to 41. He was discharged with general medical follow-up and a prednisolone weaning regime. After 1 month he re-presented to the medical take with acute bilateral visual loss (on 15mg prednisolone). This was preceded by a 2-week history of bitemporal headaches. There was no history of polymyalgia, jaw claudication or scalp tenderness. Ocular examination revealed bilateral swollen optic discs. He was admitted and treated with pulsed intravenous methylprednisolone. An MRA of his head and neck showed intracranial irregularities consistent with a cerebral vasculitis. He was started on methotrexate alongside prednisolone and referred to the regional GCA centre for tocilizumab therapy. Discussion: The frequency of ophthalmic complications in GCA is quoted tobe as highas 30%. The case abovepresentedwithnon-specific symptoms and extremely raised inflammatory markers. Despite numerous investigations including a PET scan, a definitive diagnosis was not made without the final presentationof permanent bilateral visual loss. The patient had appropriate and timely investigations for his symptoms at initial admission (blood tests, cultures, CT and PET imaging). Positive findings were appropriately investigated further. Ultimately, he was trialled with prednisolone when infection and malignancy were excluded by the medical team and discharged with follow up. Unfortunately, he was then readmitted with a dramatic relapse.
The British Society for Rheumatology recommends starting methotrexate following recurrent relapses in GCA, but we decided to start methotrexate due to the aggressive nature of his disease (sudden onset visual loss and cerebral vasculitis on MRA). Few randomised controlled studies, case-control studies and metaanalyses have looked at the efficacy and steroid-sparing effects of methotrexate introduction at diagnosis of GCA to conflicting results. Jover et al. (2001) showed that low dose methotrexate (10mg) was effective in controlling GCA disease activity. This was supported by a metaanalysis (Mahr et al., 2007) and most recently in a retrospective case-control study (Koster et al., 2019) . The larger and well-designed Hoffman et al. (2002) trial showed a small benefit from methotrexate introduction but no statisticalsignificance. There hasbeen nolarge-trialconvincing evidence of methotrexate efficacy in GCA at introduction or for relapses and this is reflected in the national guidance. However, the trials above used relatively low doses of methotrexate. Some of the trial also had short follow-up times and with slow steroid weans possibly masking a positive methotrexate effect. Key learning points: Despite the vague and nondescript presentation of this patient, focusing on subtleties from the history and having a high index of suspicion arevital to making adiagnosis of GCA. The patient had a negative PET scan despite progression to severe disease within 1 month. PET studies have shown high sensitivity and specificity values for the diagnosis of large vessel inflammation in GCA (90% and 98% respectively -Soussan et al., 2015) . However, the lack of large vesselinvolvement onthis scan was falsely reassuring. Conflicts of interest: The authors have declared no conflicts of interest.
NOT EVERY RHEUMATOLOGIC HEADACHE IS GIANT CELL ARTERITIS: A CASE OF ASEPTIC MENINGITIS ON A BACKGROUND OF RHEUMATOID ARTHRITIS
Priyan Magan 1 , Muhamad Jasim 1 , and Nick Barkham 1 The Rheumatology Centre, New Cross Hospital, Wolverhampton, United Kingdom Introduction: A 65-year-old Caucasian lady had a background of longstanding seropositive rheumatoid arthritis (RA) for which multiple disease modifying drugs and biologics had been tried, but then stopped due to either inefficacy or intolerance. She presented with possible vasculitis and was initiallytreated and investigated for giant cell arteritis (GCA). Case description: This patient presented with temporal headache and right-sided visual field loss, with tenderness over a weakly palpable right temporal artery. No jaw claudication or other cranial nerve abnormality and peripheral nervous system examination was normal. She was commenced on prednisolone and the ophthalmologist decided against temporal artery biopsy. She subsequently developed episodes of tonicclonic seizure and reduced consciousness, which would be unexplained by GCA. ESR 70 and CRP 28. ANCA and ANA negative, rheumatoid factor positive and anti-CCP antibodies>600. Gadolinium-enhanced MRI brain showed subdural effusions in the left frontal/parietal lobes alongside effacement of the gyri, indicating lepatomeningitis. Lumbar puncture showed increased cerebral spinal fluid (CSF) protein of 1.25g/L (0.1-0.4) and mildly reduced glucose of 2.1mmol/ L (2.2-3.9). CSF was negative for acid fast bacilli, lyme disease, cryptococcal antigen, PCR for viruses and TB, culture and extensive immunological screening. Tuberculosis T-Spot test was negative whilst PET-CT demonstrated widespread polyarthropathy but no evidence of an underlying malignancy. The patient was referred for meningeal biopsy; however it was considered too high-risk given her medical co-morbidities. As an inpatient, she developed pneumonia and two myocardial infarctions. For the next four months, she was seizure-free on levetiracetam, but still experienced right-sided facial twitching. She was commenced on a reducing regime of prednisolone on the assumption of rheumatoid meningitis and also given 12-month empirical therapy to cover for possibility of TB meningitis, although this was deemed less likely. Initially she responded to prednisolone but upon dose reduction, she noticed worsening incoordination and unsteadiness, with simultaneous joint flare-up, indicating that immunosuppression was beneficial to her neurological status. Azathioprine was introduced as a steroid-sparing agent but she developed abnormal liver function and hence mycophenolate has been used instead. No side effects have been reported; she has remained seizure-free and reports an improvement in her neurological status. Discussion: Initially it was appropriate to treat as GCA given very typical history. However, the presence of other unexplained symptoms and MRI findings led the decision that the diagnosis was not purely vasculitic in origin. MRI brain and CSF findings were consistent with aseptic meningitis, typically where there is meningeal inflammation with negative Gram stain and culture of CSF, often with pleocytosis. Although predominantly caused by enteroviruses; it can occur secondary to malignancy, drugs and autoimmune disease. These causes were considered, however the presence of active rheumatoid arthritis made a diagnosis of rheumatoid meningitis likely. This uncommon complication of seropositive rheumatoid arthritis was described by Bathon et al as having three hallmark neuropathological findings; rheumatoid nodules, pachymeningitis and vasculitis. A diagnostic challenge is the lack of correlation between synovitis and neurological presentation. Presentation ranges from cranial/ peripheral nerve dysfunction to seizures and altered mental state. In the CSF we expect to find high protein and reduced glucose with sporadic pleocytosis. Findings from MRI and CSF analysis can be variable. Ultimately rheumatoid meningitis as described in the literature is diagnosed by histopathology at biopsy, but this is not always available in clinical practice, and sometimes empirical treatment has tobe given. Key learning points: Rheumatoid meningitis is a rare complication of RA, but can present with stroke-like episodes or seizures, so this diagnosis should always be considered in RA patients presenting in such a way. Despite high mortality and the lack of any evidence-based guidelines, combinations of steroids alongside cyclophosphamide, azathioprine and methotrexate are reported to have improved prognosis in some patients. The lack of any RCT evidence means the condition has to be managed according to expert opinion, which may require close co-operation between specialties such as neurology, infectious diseases and rheumatology to achieve a good outcome. Conflicts of interest: The authors have declared no conflicts of interest.
AN UNCOMMON CAUSE OF PYREXIA OF UNKNOWN ORIGIN
Noora Soobraty 1 , and Michael Green 2 1 Department of Rheumatology, Midyorks NHS Trust, Wakefield, United Kingdom, and 2 Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom Introduction: We report the case of a 58-year-old lady with pre-existing primary pulmonary hypertension presenting with a pyrexia of unknown origin (PUO). On review of her previous CT imaging, it was noted that the aortic wall was thickened which prompted further investigations in the form of a PET CT and IgG subclasses that led to the final diagnosis of large vessel vasculitis (LVV) and IgG4-related disease. She was successfully treated with prednisolone and mycofenolate mofetil (MMF). Interestingly she subsequently developed neurological symptoms and diagnosed with Miller-Fisher syndrome and further down the line she was diagnosed with adrenal insufficiency(AI). Case description: A 58-year-old lady was admitted under the cardiology team in April 2014 for investigation of a PUO. The patient also complained of worsening breathless on exertion, malaise and myalgia. Past medical history revealed pulmonary arterial hypertension (diagnosed 2000) with secondary right sided heart failure, an incidental secundum ASD defect and recurrent anterior uveitis. She was on sildenafil and warfarin long term. Clinical examination did not reveal any abnormal findings. Initial investigations to rule out a bacterial cause for her symptoms were i44 27 September 2019 POSTER PRESENTATIONS performed and were unremarkable. She had a mild anaemia and persistently raised CRP. Her initial autoimmune screen showed no abnormality. An outpatient CT chest, abdomen and pelvis showed a small pericardial effusion and noevidence of malignancy. In July 2014 she was reviewed in the rheumatology clinic and in view of her symptom profile and persistently raised inflammatory markers in the absence of infection, this raised the possibility of a systemic inflammatory problem related to a vasculitis. The recent CT imaging was reviewed at the rheumatology/radiology MDT and the radiologists felt that there was some probable inflammatory change in the aorta and some wall thickening. Further investigations with PET CT confirmed inflammatory changes in the large vessels and IgG subclasses were elevated at 2.06g/L. She was started on treatment for LVV and possible IgG4 disease, initially with 40mg prednisolone and MMF was later introduced. A repeat PET in May 2015 was normal. In January 2016 she developed sudden ataxia, hyporeflexia and weakness. She was found to have positive anti-gq1 antibodies and diagnosed with Miller-Fisher syndrome. Her symptoms resolved with an increase in the prednisolone dose. She had 3 further hospital admissions, each with similar symptoms of collapse and loss of consciousness, which was subsequently felt to be due to AI. Discussion: In this patient presenting with fevers and raised inflammatory markers, the initial investigations were rightly aimed at trying to identify a source of infection as this is the main concern in a patient with an ongoing pyrexia. Reviewing the images in clinic and at our MDT meeting identified the thickened aortic wall. This was key in providing further information as to what might be the cause of the patient's presentation and led us to order the appropriate and more detailed investigations in the form of PET CT and IgG subclasses. It was not possible in this case to get a histological diagnosis and therefore, based on the elevated IgG subclasses and PET findings, a presumptive diagnosis of IgG4 related disease and LVV was made. The initial treatment choice of prednisolone 40mg is based on current practice for treating LVV. In view of the IgG4 disease and after discussion with the Immunologists, it was decided that MMF would be the most appropriate steroid-sparing agent. This case highlights the fact that making adiagnosis of largevesselvasculitis is somewhatdifficult due to the non-specific clinicalpresentationsand laboratory findings. Once the diagnosis was made, this raised the question as to whether the pulmonary hypertension was in any way connected to the LVV or coincidental. This case also highlights the fact that patients with several immune-related diseases can develop further autoimmune conditions. In this case she was initially diagnosed with a LVV and IgG4-related disease then Miller-Fisher syndrome and following that adrenal insufficiency. Is this phenomenonbecoming more common inclinicalpractice? One other point for discussion is the choice of steroid-sparing agent, in this case we opted for MMF. Is there a case forrituximab in this patient? Key learning points: This case illustrates the fact that looking at previous imaging was crucial at providing further information and decide on further imaging that would aid in the diagnosis. The CT images were reviewed with the relevant laboratory findings, clinical picture and asking the right questions to the radiologists. In this case, we asked them to have a look at the large vessels in more detail as this can sometimes be missed and not properly looked at if the radiologists are not asked to specifically look at the large vessels. The differential diagnosis for these patients are broad and include infection, malignancy and inflammatory conditions such as a vasculitis or autoinflammatory disorder. Therefore keeping an open mind where these patients are concerned is important, especially in exploring the rarer causes of sucha presentation.
There is no single diagnosis to explain all the symptoms experienced by the patient. The presence of one autoimmune disease should alert one to watch for another onein these patients. A multi-disciplinary team approach to the management of these complex patients with several autoimmune disorders, is essential. Reviewing the images with the radiologists helped identify thickening of the aortic wall. The regional immunology team was also involved in discussions about long-term management. The Neurology team was also involved and diagnosed Miller-Fisher syndrome.
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BINOCULAR SIGHT LOSS: UNCOMMON, YET A DEVASTATING COMPLICATION OF GCA
Liubov Borukhson 1 , Abdul Kayani 1 , and Bhaskar Dasgupta 1 1 Rheumatology, Southend University Hospital, Southend, United Kingdom Introduction: GCA (giant cell arteritis) affects cranial branches of the arteries from aortic arch, especially the superficial temporal artery and vessels supplying the eye. Ophthalmic manifestations of GCA are characterised by the vasculitis of the ophthalmic artery and its branches. We present a case of a patient who developed the binocular sequential permanent vision loss secondary to GCA due to the delayeddiagnosis. Case description: A seventy-six year-old lady with a background of type two diabetes mellitus, hypertension and dyslipidemia and hemicolectomy for appendix tumour two years ago (no recurrence) was admitted with blurring of vision in the eye. She did not complain about other symptoms, however, on direct questioning she admitted six weeks history of weight loss (2.5 stones), severe tiredness and occasional night sweats, mild left sided temporal headache. She was initiated on 60mg of prednisolone. One week prior to admission she had right eye CRAO diagnosed by the ophthalmology team with preceding three weeks history of right eye blurring of vision. CRP at that time was 12 g/L and GCA was not considered likely. Following her permanent right sided vision loss, she was referred to stroke team for further management and was given aspirin. Her CT and MRI brain scans were unremarkable, USS carotid arteries revealing diffuse intimal thickeningin all the arteries of the neck. On assessment in the rheumatology fast track clinic she denied any associated jaw/tongue/arms claudication and no proceeding or historical PMR symptoms. She had mild left sided temporal artery tenderness and decreased temporal artery pulses bilaterally, no vision in the right eye along with the blurring in the left eye. There were no audible bruits in carotid, axillary, femoral arteries. Her acute phase maker (CRP) was mild but persistently elevated with a maximum level of 12 g/L for one week prior the admission. USS showed features consistent with GCA with extensive non-compressible halo signs in temporal arteries and its branches bilaterally. An urgent ophthalmology review revealed AION changes in the left eye, her vision deteriorated over the next forty-eight hours despite the initiation of high dose intravenous methylprednisolone. The patient was also started on tocilizumabinfusion inan attempt to reverse the sight loss. Discussion: The ophthalmic manifestations of GCA range from AION (anterior ischaemic optic neuropathy), CRAO (anterior central retinal artery occlusion), cilioretinal artery occlusion to occipital lobe infarcts, transient monocular vision loss, photopsias or diplopia. Ophthalmic GCA is an emergency and requires urgent ophthalmological evaluations and initiation of treatment with high dose of steroids to avoid permanent loss of vision. The reported incidence of visual symptoms in GCA ranges widely from 12% to 70% of cases. GCA is often associated with constitutional symptoms such as weight loss, night sweats, fevers, systemic inflammatory response with elevated inflammatory markers. However, it had been reportedthat this can be very mild inischaemic GCA. The diagnosis of GCA in this particular case was delayed for approximately six weeks due to the atypical initial presentation with mainly constitutional symptoms and unilateral vision blurring as well as mildly elevated inflammatory markers. A collaboration of three teams (namely ophthalmology, stroke and rheumatology) proved necessary to initiate high dose steroid treatment and tocilizumab. However, patient still suffered from permanent binocular vision loss. She was registered blind and will infuturerequire extensive physical and psychological support. Key learning points: Despite the recent advances and increased awareness with good availability of fast track GCA services, cases of bilateral blindness are still observed. This is due to a lack of awareness of atypical non-cranial symptoms that frequently accompany a GCA ischaemic presentation. Inflammatory markers are often only mildly elevated in such cases. We suggest a heightened public and professional awareness program to mitigate this irreversible disastrous complication.
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